These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Dad T; Tighiouart H; Joseph A; Bostom A; Carpenter M; Hunsicker L; Kusek JW; Pfeffer M; Levey AS; Weiner DE Am J Kidney Dis; 2016 Aug; 68(2):277-286. PubMed ID: 26947217 [TBL] [Abstract][Full Text] [Related]
9. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Righetti M; Serbelloni P; Milani S; Ferrario G Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160 [TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Bostom AG; Carpenter MA; Kusek JW; Hunsicker LG; Pfeffer MA; Levey AS; Jacques PF; McKenney J; Am Heart J; 2006 Sep; 152(3):448.e1-7. PubMed ID: 16923411 [TBL] [Abstract][Full Text] [Related]
11. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. Toole JF; Malinow MR; Chambless LE; Spence JD; Pettigrew LC; Howard VJ; Sides EG; Wang CH; Stampfer M JAMA; 2004 Feb; 291(5):565-75. PubMed ID: 14762035 [TBL] [Abstract][Full Text] [Related]
12. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Bostom AG; Carpenter MA; Hunsicker L; Jacques PF; Kusek JW; Levey AS; McKenney JL; Mercier RY; Pfeffer MA; Selhub J; Am J Kidney Dis; 2009 Jan; 53(1):121-8. PubMed ID: 19022547 [TBL] [Abstract][Full Text] [Related]
13. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. Albert CM; Cook NR; Gaziano JM; Zaharris E; MacFadyen J; Danielson E; Buring JE; Manson JE JAMA; 2008 May; 299(17):2027-36. PubMed ID: 18460663 [TBL] [Abstract][Full Text] [Related]
14. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. ; Armitage JM; Bowman L; Clarke RJ; Wallendszus K; Bulbulia R; Rahimi K; Haynes R; Parish S; Sleight P; Peto R; Collins R JAMA; 2010 Jun; 303(24):2486-94. PubMed ID: 20571015 [TBL] [Abstract][Full Text] [Related]
15. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Bostom AG; Shemin D; Gohh RY; Beaulieu AJ; Bagley P; Massy ZA; Jacques PF; Dworkin L; Selhub J Kidney Int Suppl; 2001 Feb; 78():S246-52. PubMed ID: 11169020 [TBL] [Abstract][Full Text] [Related]
16. Homocysteine and renal disease. van Guldener C; Robinson K Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849 [TBL] [Abstract][Full Text] [Related]
17. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754 [TBL] [Abstract][Full Text] [Related]
18. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173 [TBL] [Abstract][Full Text] [Related]
19. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Clarke R; Armitage J Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852 [TBL] [Abstract][Full Text] [Related]
20. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Saposnik G; Ray JG; Sheridan P; McQueen M; Lonn E; Stroke; 2009 Apr; 40(4):1365-72. PubMed ID: 19228852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]